Charles A Conrad

Author:

Charles P. Conrad

ISBN #:

0789008793

Author:

Charles Conrad

ISBN #:

0155007866

Author:

Charles Conrad

ISBN #:

0155035703

Author:

Charles Conrad

ISBN #:

0155063480

Author:

Charles Conrad

ISBN #:

0030304237

Author:

Charles Conrad

ISBN #:

0030616697

Author:

Charles Conrad

ISBN #:

0534636217

Author:

Charles Conrad

ISBN #:

0893917958

US Patent:

7137979, Nov 21, 2006

Filed:

Oct 2, 2003

Appl. No.:

10/677737

Inventors:

Robert Conrad - Spring TX, US
Charles Conrad - Spring TX, US

Assignee:

Tyrell, Inc. - Houston TX

International Classification:

A61B 18/04

US Classification:

606 31, 606 29, 607 98

Abstract:

Methods and devices for the treatment of skin lesions resulting from bacterial, fungal or viral infections or from exposure to irritants are disclosed. The invention relates methods and devices for delivering a controlled dose of thermal energy to the infected or irritated tissue and thereby speed the recovery process.

US Patent:

8143412, Mar 27, 2012

Filed:

Jun 26, 2009

Appl. No.:

12/989944

Inventors:

Waldemar Priebe - Houston TX, US
Stanislaw Skora - Houston TX, US
Timothy Madden - Sugar Land TX, US
Izabela Fokt - Houston TX, US
Charles Conrad - Spring TX, US

International Classification:

C07D 213/57
A61K 31/44

US Classification:

546330, 514357

Abstract:

Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.

US Patent:

8182475, May 22, 2012

Filed:

Oct 2, 2006

Appl. No.:

11/541805

Inventors:

Robert Conrad - Houston TX, US
Charles Conrad - Houston TX, US

Assignee:

LumaTherm, Inc. - Austin TX

International Classification:

A61B 18/04

US Classification:

606 31, 606 29, 607 98

Abstract:

Methods and devices for the treatment of skin lesions resulting from bacterial, fungal or viral infections or from exposure to irritants are disclosed. The invention relates methods and devices for delivering a controlled dose of thermal energy to the infected or irritated tissue and thereby speed the recovery process.

US Patent:

8299033, Oct 30, 2012

Filed:

Oct 19, 2009

Appl. No.:

12/581550

Inventors:

Waldemar Priebe - Houston TX, US
Slawomir Szymanski - Houston TX, US
Izabela Fokt - Houston TX, US
Charles Conrad - Houston TX, US
Timothy Madden - Sugar Land TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A01N 43/04
A61K 31/70
C07H 1/00

US Classification:

514 23, 536 111

Abstract:

Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof.

US Patent:

8450337, May 28, 2013

Filed:

Sep 30, 2009

Appl. No.:

12/570819

Inventors:

Waldemar Priebe - Houston TX, US
Charles Conrad - Spring TX, US
Timothy Madden - Sugar Land TX, US

Assignee:

Moleculin, LLC - Houston TX

International Classification:

A61K 31/44
A61K 31/16
A61K 31/275
A61P 17/06

US Classification:

514277, 514863, 514 186, 514390, 514392, 558390, 558392

Abstract:

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0. 01% to about 20%, preferably, from about 0. 1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

US Patent:

8637675, Jan 28, 2014

Filed:

Feb 21, 2012

Appl. No.:

13/401161

Inventors:

Waldemar Priebe - Houston TX, US
Stanislaw Skora - Houston TX, US
Timothy Madden - Sugarland TX, US
Izabela Fokt - Houston TX, US
Charles Conrad - Spring TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31/44
C07D 213/57

US Classification:

546330, 514345

Abstract:

Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.

US Patent:

20030082800, May 1, 2003

Filed:

May 1, 2002

Appl. No.:

10/136218

Inventors:

Charles Conrad - Houston TX, US
Yin Chen - Pearland TX, US

Assignee:

CytoGenix, Inc. - Houston TX

International Classification:

C12N015/00
C12N005/06

US Classification:

435/325000, 435/320100

Abstract:

An expression vector for altering expression of a target nucleic acid sequence in a host cell by production of single-stranded cDNA (ssDNA) in the host cell in vivo. The expression vector is comprised of a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3′ to the inverted tandem repeat, and a reverse transcriptase/RNAse H coding gene, and may be transfected into the host cell. Transcription of the cassette by the host cell produces an RNA template which is reverse transcribed with the product of the RT coding gene to produce ssDNA of a specified sequence. The ssDNA is modified to remove flanking vector sequences by taking advantage of the “stem-loop” structure of the ssDNA, which forms as a result of the inverted tandem repeat that allows the ssDNA to fold back on itself, forming a double stranded DNA stem. The double-stranded stem may contain one or more restriction endonuclease recognition sites and the loop, which remains as ssDNA, can be any desired nucleotide sequence. This design allows the double-stranded stem of the stem-loop intermediate to be cleaved by the desired corresponding restriction endonuclease(s) and the loop portion is then released as a linearized, single-stranded piece of DNA. The resulting ssDNA binds to an endogenous target nucleic acid sequence to alter the expression of that sequence for such therapeutic purposes as gene activation or inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, or interfering with RNA splicing functions.

US Patent:

20030138405, Jul 24, 2003

Filed:

Apr 17, 2002

Appl. No.:

10/124608

Inventors:

Juan Fueyo - Houston TX, US
Athanassios Kyritsis - Stavraki, GR
Polly Lee - Houston TX, US
Victor Levin - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houston TX, US

International Classification:

A61K048/00
C12N007/00
C12N015/861

US Classification:

424/093200, 435/235100, 435/456000

Abstract:

The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.